Synthetic Probes of Protein Prenylation
Synthetic Probes of Protein Prenylation
批准号:
7619436
负责人:
H Peter Spielmann
金额:
$31.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-05-01 至 2012-03-31
关键词:
Active SitesAntibodiesBinding SitesBiochemicalBiologicalBiological AssayBiological ProcessBiologyCellsChemical StructureDependenceDevelopmentDimethylallyltranstransferaseDiscriminationDrug DesignEnzymesEventExhibitsFarnesyl Transferase InhibitorFundingFutureGoalsGrowthImmunoprecipitationLeadLipidsMalignant NeoplasmsMethodsModificationMolecular TargetMonoclonal AntibodiesOncogenesPathway interactionsPeptidesPlayPost-Translational Protein ProcessingPreparationProcessProtein IsoprenylationProteinsProteomicsReagentResearchRoleScreening procedureSignal TransductionSite-Directed MutagenesisSpecificitySubstrate SpecificityTechniquesTestingTherapeutic InterventionToxic effectTransformed Cell Lineanalogcancer therapycellular targetingchemical synthesisclinical effectcytotoxicitydesignenzyme substrategeranylgeranyl diphosphatein vivoinhibitor/antagonistinnovationisoprenoidlipophilicitynovelprenylprenylationprogramsprotein farnesyltransferaseprotein functionprotein geranylgeranyltransferasepublic health relevancetooltumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Covalent modification by isoprenoid lipids (prenylation) is a critical post-translational event for many proteins involved in cellular signaling and cancer. The primary goal of this research program is to design and test prenyl function inhibitors and to identify and characterize proteins that are farnesylated in vivo. The studies outlined in this proposal will result in the preparation of new tools to probe the specificity of the prenyltransferases protein- farnesyltransferase (FTase) and protein-geranylgeranyltransferase (GGTase-I), enable further development of prenyl function inhibitors and identify new prenylated proteins as potential targets for therapeutic intervention. By varying the chemical structure of the prenyl lipid, we are developing reagents to probe the biological function of the posttranslational modification. Taking advantage of the fact that the prenyl group forms a substantial part of the peptide substrate binding site in the prenyltransferases has allowed us to develop peptide selective inhibitors of prenyl function. These unnatural analogues may allow for the selective interference with specific prenylation targets and may provide lead compounds to alleviate the potential toxicity associated with complete inhibition of protein prenylation. In particular, the unnatural analogues may be useful to obtain a more complete understanding of the role that alternative prenylation plays in Farnesyl transferase inhibitor (FTI) evasion by oncogenes such as K-Ras. Critical to understanding the clinical effects of existing and future FTIs and geranylgeranyl transferase inhibitors (GGTIs), is the identification of in vivo substrates of FTase and GGTase-I. Our innovative strategy of using unnatural, transferable prenyl analogues and analogue specific monoclonal antibodies to identify prenylated cellular proteins will provide valuable information on the cellular targets of inhibitors of prenylation. We expect these studies to result in the identification of previously unknown prenylated proteins. The specific aims of this project are: 1) Synthesis of farnesyl and geranylgeranyl diphosphate analogues to study protein prenylation. 2) Screening these compounds for substrate specificity of FTase and GGTase-I and development of prenyl function inhibitors. 3) Identification of prenylated proteins in cells. The results from these studies may provide leads to new molecules to treat cancer and also identify new molecular targets to develop anti-cancer therapies.
PUBLIC HEALTH RELEVANCE Substantial evidence points to the central role of proteins normally modified by a prenyl group in cancer progression. We propose to design and test prenyl function inhibitors and to identify and characterize proteins that are modified with prenyl groups. The results from these studies may provide leads to new molecules to treat cancer and also identify new molecular targets to develop future anti-cancer therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Synthetic Probes of Protein Prenylation
-
批准号:8052002
-
项目类别:
-
资助金额:$8.5万
-
财政年份:2010
-
负责人:H Peter Spielmann
-
依托单位:
Synthetic Probes of Protein Prenylation
-
批准号:6745114
-
项目类别:
-
资助金额:$28.96万
-
财政年份:2002
-
负责人:H Peter Spielmann
-
依托单位:
Synthetic Probes of Protein Prenylation
-
批准号:7364926
-
项目类别:
-
资助金额:$9.77万
-
财政年份:2002
-
负责人:H Peter Spielmann
-
依托单位:
Synthetic Probes of Protein Prenylation
-
批准号:6621477
-
项目类别:
-
资助金额:$28.96万
-
财政年份:2002
-
负责人:H Peter Spielmann
-
依托单位:
Synthetic Probes of Protein Prenylation
-
批准号:8070533
-
项目类别:
-
资助金额:$30.51万
-
财政年份:2002
-
负责人:H Peter Spielmann
-
依托单位:
Synthetic Probes of Protein Prenylation
-
批准号:6889530
-
项目类别:
-
资助金额:$28.96万
-
财政年份:2002
-
负责人:H Peter Spielmann
-
依托单位:
Synthetic Probes of Protein Prenylation
-
批准号:7461917
-
项目类别:
-
资助金额:$28.96万
-
财政年份:2002
-
负责人:H Peter Spielmann
-
依托单位:
Synthetic Probes of Protein Prenylation
-
批准号:6434588
-
项目类别:
-
资助金额:$26.59万
-
财政年份:2002
-
负责人:H Peter Spielmann
-
依托单位:
STRUCTURE OF PSORALEN MODIFIED DNA OLIGOMER BY NMR
-
批准号:3046458
-
项目类别:
-
资助金额:$2.27万
-
财政年份:1993
-
负责人:H Peter Spielmann
-
依托单位:
STRUCTURE OF PSORALEN MODIFIED DNA OLIGOMER BY NMR
-
批准号:2169528
-
项目类别:
-
资助金额:$2.86万
-
财政年份:1993
-
负责人:H Peter Spielmann
-
依托单位:
海外基金